Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Stip

Showing results (261-270 of 278) with videos related to

Pageof 28
Sort By:
JAMA Network Open|November 22, 2024
Medication Exposure and Mortality in Patients With SchizophreniaSébastien Brodeur, Yohann M Chiu, Josiane Courteau, et al.
BMC Psychiatry|October 11, 2025
Psychotropic-associated delusional pseudo-gender dysphoria: a case reportKarim Abdel Aziz, Abeer Saleh Al Ammari, Mouza Sultan Alzaabi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 31, 2021
Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trialFlorence Morissette, Violaine Mongeau-Pérusse, Elie Rizkallah, et al.
Frontiers in Psychiatry|June 2, 2011
Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with QuetiapineSimon Zhornitsky, Emmanuel Stip, Joelle Desfossés, et al.
Neuroscience and Biobehavioral Reviews|December 4, 2022
Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trialsDanilo Arnone, Omar Omar, Teresa Arora, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|May 8, 2007
Treating delusional disorder: a comparison of cognitive-behavioural therapy and attention placebo controlKieron O'Connor, Emmanuel Stip, Marie-Claude Pélissier, et al.
Frontiers in Pharmacology|January 4, 2021
The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19Emmanuel Stip, Tahir A Rizvi, Farah Mustafa, et al.
Clinical Schizophrenia & Related Psychoses|July 29, 2015
Sex, Age, Symptoms and Illness Duration and Their Relation with Gyrification Index in SchizophreniaAdham Mancini-Marïe, Uicheul Yoon, Jose Jiminez, et al.
The Journal of International Medical Research|September 22, 2020
Measures of gluten-related reactivity in children with autism spectrum disorders in the absence of overt gastrointestinal symptoms: a pilot study from the United Arab EmiratesMohamed Abdel-Maksoud, Dina Aly El-Gabry, Tahani Al Kayoumi, et al.
Journal of Psychiatry & Neuroscience : JPN|September 8, 2007
Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatmentRic M Procyshyn, Kishor M Wasan, Allen E Thornton, et al.
Pageof 28

Showing results (261-270 of 278) with videos related to

Sort By:
Pageof 28
JAMA Network Open|November 22, 2024
Medication Exposure and Mortality in Patients With SchizophreniaSébastien Brodeur, Yohann M Chiu, Josiane Courteau, et al.
BMC Psychiatry|October 11, 2025
Psychotropic-associated delusional pseudo-gender dysphoria: a case reportKarim Abdel Aziz, Abeer Saleh Al Ammari, Mouza Sultan Alzaabi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 31, 2021
Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trialFlorence Morissette, Violaine Mongeau-Pérusse, Elie Rizkallah, et al.
Frontiers in Psychiatry|June 2, 2011
Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with QuetiapineSimon Zhornitsky, Emmanuel Stip, Joelle Desfossés, et al.
Neuroscience and Biobehavioral Reviews|December 4, 2022
Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trialsDanilo Arnone, Omar Omar, Teresa Arora, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|May 8, 2007
Treating delusional disorder: a comparison of cognitive-behavioural therapy and attention placebo controlKieron O'Connor, Emmanuel Stip, Marie-Claude Pélissier, et al.
Frontiers in Pharmacology|January 4, 2021
The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19Emmanuel Stip, Tahir A Rizvi, Farah Mustafa, et al.
Clinical Schizophrenia & Related Psychoses|July 29, 2015
Sex, Age, Symptoms and Illness Duration and Their Relation with Gyrification Index in SchizophreniaAdham Mancini-Marïe, Uicheul Yoon, Jose Jiminez, et al.
The Journal of International Medical Research|September 22, 2020
Measures of gluten-related reactivity in children with autism spectrum disorders in the absence of overt gastrointestinal symptoms: a pilot study from the United Arab EmiratesMohamed Abdel-Maksoud, Dina Aly El-Gabry, Tahani Al Kayoumi, et al.
Journal of Psychiatry & Neuroscience : JPN|September 8, 2007
Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatmentRic M Procyshyn, Kishor M Wasan, Allen E Thornton, et al.
Pageof 28